A comprehensive review in Clinical Cancer Bulletin maps how CAR-T therapy is pushing beyond blood cancers and into solid tumors and autoimmune diseases. The paper summarizes regulatory progress across 2024 approvals and positions CAR-T as a platform technology with expanding indications and engineering adaptations. By late 2024, the review notes that twelve CAR-T products had received U.S. approval, providing a foundation for development in new disease categories where efficacy barriers—such as trafficking, persistence and tumor microenvironment—are more difficult. The review’s value for industry is its consolidation of current strategies and remaining gaps, including target selection constraints and how different “beyond hematologic malignancy” designs attempt to overcome immune escape. As CAR-T approaches mature, the key challenge is scaling durable, safe activity across heterogeneous tissue environments—especially where autoimmune risk and off-target effects require tighter control.